The combined sales of Taiji Group's Qumei and another drug, Rosiglitazone Sodium Tablets, in 2009 were approximately 2.5 billion yuan, and it is estimated that the combined sales in 2010 will exceed 3 billion yuan, accounting for about 17% of the company's industrial sales revenue and contributing around 30% to the gross profit. The total amount of returns for Taiji Group is still being calculated. According to its announcement on October 30th, the halt in sales this time will impact the company's sales revenue by nearly 40 million yuan this year, accounting for about 0.8% of the company's sales revenue.